This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Patat, A. Articles by Rosenzweig, P. Search for Related Content PubMed Articles by Patat, A. Articles by Rosenzweig, P. Social Bookmarking                         What's this?

Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers

Synthélabo Recherche, Clinical Research Department, Clinical Pharmacology Section, 31, Av. Paul Vaillant Couturier, B. P. 110, 92225 Bagneux Cedex

M.C. Perault

CHU, Clinical Pharmacology Department, Pavillion de Blaye, Cité Hospitalière de la Miletrie, 86021 Poitiers

B. Vandel

CHU, Clinical Pharmacology Department, Pavillion de Blaye, Cité Hospitalière de la Miletrie, 86021 Poitiers

Ph. Danjou

Hôpital La Pitié Salpêtrière, Clinical Pharmacology Department, 47, Bd de l'Hôpital, 75013 Paris, France

S. Brohier

Synthélabo Recherche, Clinical Research Department, Clinical Pharmacology Section, 31, Av. Paul Vaillant Couturier, B. P. 110, 92225 Bagneux Cedex

I. Zieleniuk

Synthélabo Recherche, Clinical Research Department, Clinical Pharmacology Section, 31, Av. Paul Vaillant Couturier, B. P. 110, 92225 Bagneux Cedex

P. Rosenzweig

Synthélabo Recherche, Clinical Research Department, Clinical Pharmacology Section, 31, Av. Paul Vaillant Couturier, B. P. 110, 92225 Bagneux Cedex

Potential interactions between the imidazopyridine anxiolytic alpidem and the full benzodiazepine agonist lorazepam were assessed in a randomized, double-blind, four-way cross-over, placebo-controlled study in 16 healthy young male volunteers. Each volunteer received alpidem, 50 mg, or a placebo twice daily for 8 days with a 1- week wash-out interval. The interaction between alpidem, at the steady state, and a single oral dose of lorazepam 2 mg or a placebo was assessed after concomitant administration on days 7 or 9 of each treatment period. Psycho motor performance and cognitive function were evaluated before and 2, 4, 6 and 8 h post-dose, using objective tests [critical flicker fusion threshold (CFF), choice reaction time (CRT), digit-symbol substitution (DSST), body sway and short-term memory (Sternberg memory scanning)] and self-ratings [line analogue rating scales: (LARS)]. Long-term memory (delayed free recall and recognition of pictures) was assessed before the dose and 2 and 4 h post-dose. Pharmacodynamic interactions were evaluated by applying repeated measures ANOVA to a 2 x 2 factorial interaction model. Alpidem, 50 mg twice daily at the steady state, was free of any clinically relevant detrimental effects on skilled performance, information processing or memory. In contrast, a single 2 mg dose of lorazepam induced marked impairment of psychomotor performance and cognitive function (significant reductions in CFF and DSST and increases in CRT and body sway), as well as subjective sedation from 2 to 8 h post-dose, depending on the test used. In addition, lorazepam induced anterograde amnesia, characterized by a decrease in delayed free recall and recognition, and a deficit in short-term memory. Finally, alpidem 50 mg did not potentiate the detrimental effects of lorazepam 2 mg. On the contrary, alpidem significantly antagonized the lorazepam-induced CRT increase and anterograde amnesia, and produced similar trends on most of the other cognitive parameters; thus, the results obtained with the combination of alpidem and lorazepam consistently indicated less impairment than those measured after lorazepam alone. These results are consistent with the suggested partial agonsist properties of alpidem at the benzodiazepine receptor and indicate that such properties can be assessed in humans based on antagonism of the effects of a full agonist.

Key Words: alpidem • lorazepam • partial agonist • benzodiazepine • anxiolytics • interaction • psychomotor performance • memory • cognitive function • psychopharmacology

Journal of Psychopharmacology, Vol. 9, No. 2, 91-101 (1995)
DOI: 10.1177/026988119500900203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Jackson, D. Stephens, and T. Duka Gender differences in response to lorazepam in a human drug discrimination study J Psychopharmacol, November 1, 2005; 19(6): 614 - 619. [Abstract] [PDF]